In this study, we investigated the clinicopathological features of HER2 low expression based on male breast cancer population, and also focused on the expression of HER2 ultra-low in male breast cancer, and the results showed that the incidence of HER2 low expression was significantly higher in male breast cancer than in female breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.